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We investigated the cardiovascular effects induced by the nitric oxide donor Cyclohexane
Nitrate (HEX). Vasodilatation, NO release and the effects of acute or sub-chronic
treatment with HEX on cardiovascular parameters were evaluated. HEX induced
endothelium-independent vasodilatation (Maximum effect [efficacy, ME]= 100.4± 4.1%;
potency [pD2]= 5.1± 0.1). Relaxation was attenuated by scavenging nitric oxide (ME=
44.9± 9.4% vs. 100.4± 4.1%) or by inhibiting the soluble guanylyl cyclase (ME= 38.5±
9.7% vs. 100.4± 4.1%). In addition, pD2 was decreased after non-selective blockade of
K+ channels (pD2= 3.6± 0.1 vs. 5.1± 0.1) or by inhibiting KATP channels (pD2= 4.3±
0.1 vs. 5.1 ± 0.1). HEX increased NO levels in mesenteric arteries (33.2 ± 2.3 vs. 10.7 ±
0.2 au, p < 0.0001). Intravenous acute administration of HEX (1–20mg/kg) induced
hypotension and bradycardia in normotensive and hypertensive rats. Furthermore,
starting at 6 weeks after the induction of 2K1C hypertension, oral treatment with the
HEX (10mg/Kg/day) for 7 days reduced blood pressure in hypertensive animals (134 ±
6 vs. 170± 4mmHg, respectively). Our data demonstrate that HEX is a NO donor able to
produce vasodilatation via NO/cGMP/PKG pathway and activation of the ATP-sensitive
K+ channels. Furthermore, HEX acutely reduces blood pressure and heart rate as well
as produces antihypertensive effect in renovascular hypertensive rats.
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Introduction
Arterial hypertension is a chronic condition characterized by high levels of blood
pressure (BP) and is considered the main cause of morbidity and mortality worldwide
(Chobanian, 2011; World Health Organization, 2013). The interaction between
numerous factors such as genetic, physiological, and environmental characteristics
has been implicated in the pathophysiology of hypertension (Montezano and Touyz,
2012). Currently, it has been well established that the decreased in nitric oxide (NO)
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levels and reduced antioxidant capacity in the vessels, heart,
brain, and kidneys may play a key role in the pathogenesis
and maintenance of arterial hypertension (Puddu et al., 2008;
Sugamura and Keaney, 2011).
Nitric oxide (NO) is the major endothelium-derived relaxing
factor (EDRF) produced when nitric oxide synthase (NOS)
family catabolizes the conversion of amino acid l-arginine to
l-citrulline (Palmer et al., 1988). NO participates in maintaining
and regulating BP due its role in the adjustments of systemic
vascular resistance (Wilkinson et al., 2004). In vascular smooth
muscle cells (VSMCs), NO activates the soluble guanylyl cyclase
(sGC) enzyme producing a second messenger called cyclic
guanosine monophosphate (cGMP) that activates the specific
cGMP-dependent protein kinase (PKG), which is themain kinase
mediating vasodilation (Walford and Loscalzo, 2003; Bryan et al.,
2009). In addition, NO can directly activate protein and ion
channels to promote vasodilation (Bolotina et al., 1994). An
enhanced inactivation and/or reduced synthesis of NO are related
to cardiovascular disorders such as hypertension (Massion et al.,
2005; Naseem, 2005).
Therapies targeting to increase NO levels have great
applicability in cardiovascular diseases. NO donors (e.g.,
nitroglycerin and sodium nitroprusside) have been used in
clinical practice for decades against angina pectoris, pulmonary
hypertension, and cardiac ischemia (Münzel et al., 2011).
However, tolerance developed after the long-term use of these
agents impairs the chronic treatment of hypertension (Napoli
and Ignarro, 2003; Csont and Ferdinandy, 2005). Considering the
clinical potential for NO donors, we synthesized the cyclohexane
nitrate (HEX) from cliclohexanol as illustrated in the synthetic
route presented in Figure 1. Therefore, our aims were: (a)
characterize this novel organic nitrate as a NO donor; and (b)
evaluate its effects on cardiovascular system of normotensive
and hypertensive rats. Our data show that HEX increases NO
levels in endothelium-denudated mesenteric arteries, promoting
vasorelaxation by the activation of NO/cGMP/PKG pathway
and ATP-sensitive K+ channel (KATP). Furthermore, we
experimentally demonstrated that HEX is able to reduce blood
pressure in hypertensive rats.
Materials and Methods
Animals
All procedures were approved by Federal University of Paraiba
Animal Care and Use Committee (CEUA/UFPB # 604/14). Male
Wistar rats (250–300 g) were housed in a temperature-controlled
room, 12:12-h light–dark cycle with free access to standard
FIGURE 1 | Synthetic route for obtaining the cyclohexane nitrate (HEX).
rat chow (Labinar, Purina, Paulinea, SP, Brazil) and water.
Renovascular hypertension (2K1C model) was induced in rats
as previously described (Botelho-Ono et al., 2011; Mendes-
Junior et al., 2013). In brief, under combined ketamine and
xylazine anesthesia (75 and 10mg/kg, i.p., respectively), a
midline abdominal incision was made. The right renal artery was
exposed and isolated over a short segment by blunt dissection.
A U-shaped silver clip (0.2mm internal diameter) was placed
over the vessel at a site proximal to the abdominal aorta and the
wound closed and sutured. A sham procedure, which entailed
the entire surgery with the exception of renal artery clipping,
served as control. After the procedures, rats returned to their
home cages and remained untouched for 6 weeks in order to
develop hypertension.
Synthesis of Cyclohexane Nitrate
In volumetric balloon (100mL) equipped with a magnetic
agitator and a thermometer, 10mL of acetic anhydride (0.06mol)
was added, followed by 10mL of fuming nitric acid (0.06mol).
The temperature was set to 5◦C. The amount of fuming nitric
acid required was slowly added to the solution. Next, 10mL of
ciclohexanol (0.05mol) was added to the solution. The balloon
was agitated at 200 rpm for 30min. The reaction was stopped by
adding cold distilled water (2x the initial volume of the solution).
The reaction results in a biphasic solution. The aqueous phase is
neutralized by adding sodium bicarbonate and the organic phase
is treated with sodium sulfate to remove humidity. The reaction
is illustrated in Figure 1.
Nitric Oxide Measurements by Epifluorescence
Microscopy
Normotensive animals were euthanized and the cranial
mesenteric artery was collected and sectioned in rings
(2–3mm). The rings were kept in physiological Tyrode’s
solution (composition in mmol/L: NaCl 158.3; KCl 4.0; CaCl2
2.0; MgCl2 1.05; NaH2PO4 0.42; NaHCO3 10.0 and glucose
5.6), at 37◦C and pre-incubated for 30min in the darkness
with 4,5-diaminofluorescein diacetate (DAF-2 DA; 10mM;
Calbiochem, San Diego, CA, USA), an intracellular fluorescent
probe for NO. Tissues were washed and incubated with: HEX
(1mM); HEX (1mM) + L-NNA (100µM); GTN (10µM);
or GTN (10µM) + L-NNA (100µM) for 30min. A series
of experiments was performed only by incubating the probe
to measure the baseline fluorescence. For cryostat sectioning,
tissues were previously fixed in OCT embedding compound
and frozen at –20◦C. Sections (8µm) were cut on a CM 1900
cryostat (Leica Inc., Deerfield, IL, USA) and mounted on slides
and cover slips. The 4′,6-diamidino-2-phenylindole stain (DAPI)
was used to assist with the cell nucleus observation. The cytosolic
NO level was assessed by exciting DAF-2 DA in 480 nm using
a xenon lamp and measuring the fluorescence at 490–530 nm
in epifluorescence microscope (Nikon Eclipse TI, Tokyo,
Japan). The relative fluorescence intensity was calculated from
images obtained using a digital camera (DEI-470, Optronics
Engineering, Goleta, CA) and ImageJ software 1.42q (Wayne
Rasband, National Institutes of Health, USA). The NO content
was obtained by the change in the intensity of fluorescence (IF),
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which was calculated by the difference between the final (IFf) and
initial (IFi) florescence converted in percentage of the baseline as
%1IF= (IFf – IFi/IFf)× 100.
Vascular Reactivity Studies
Cranial mesenteric artery rings (1–2mm) were obtained as
described above and mounted vertically on two 1-shaped
stainless steel wires in a 10-ml tissue chamber connected to a
tension transducer (PowerLab™, ADInstruments, MA, EUA).
The preparations were stabilized under 0.75 g resting tension
for 1 h. The tissue viability was verified by phenylephrine (PHE,
10µM) added to the bath and the presence of functional
endothelium was assessed by acetylcholine (ACH, 10µM).
Experiments have been conducted in intact and endothelium-
denudated mesenteric artery rings. Mesenteric artery rings
were pre-contracted using PHE (1µM). After the contraction
plateau was reached, HEX (10−10–10−3 mM) was added to the
organ bath in order to build a concentration-response curve.
Data were expressed as maximum effect (ME) and potency
(pD2). The ME is related to the efficacy of the drug while
the pD2 refers to the potency of a drug. pD2 is the negative
logarithm to base 10 of the EC50. In independent protocols,
the preparations were pre-incubated (30min) with: 2-phenyl-
4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide (PTIO, 300µM),
a NO scavenger or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-
one (ODQ, 10mM), a soluble guanylyl cyclase inhibitor or
tetraethylammonium (TEA, 3mM), a non-selective K+ channels
blocker or TEA, 1mM, a large conductance Ca2+−sensitive
K+ channel blocker or glibenclamide (GLIB, 1mM), a KATP
blocker or 4-aminopyridine (4-AP, 1mM), a voltage-operated
K+ channel blocker. All drugs were obtained from Sigma-
Aldrich (São Paulo-SP, Brazil). ODQ and GLIB were solubilized
in DMSO and the others compounds were dissolved in
distilled water. In functional studies using ODQ and GLIB,
the final concentration of DMSO never exceeded 0.01% in the
bath and had no effect when tested in control preparations
(data not shown).
Acute Changes in Cardiovascular Parameters of
Rats Treated with HEX
The rats were anesthetized with ketamine and xylazine (75
and 10mg/kg, intraperitoneal [IP], respectively). Polyethylene
cannulae were inserted into the abdominal aorta and inferior
vena cava through femoral artery and vein for arterial pressure
recordings and drug injections, respectively. Blood pressure
and heart rate measurements were recorded 24 h after catheter
implantation in conscious rats using a pressure transducer
coupled to an acquisition system (PowerLab; ADInstruments,
Castle Hill, NSW, Australia) connected to a computer running
LabChart 5.0 software (ADInstruments). HEX was dissolved in
saline solution and administered through venous catheter after
20min of baseline recordings. Blood pressure and heart rate were
evaluated before and after the administration of HEX (1; 5; 10;
20mg/kg, intravenous injection [IV], randomly). The interval
between doses was 15min. Data were expressed as changes
in mean arterial pressure (1MAP) and changes in heart rate
(1HR).
Sub-chronic Treatment with HEX in Hypertensive
Rats
Animals were anaesthetized with ketamine and xylazine (75 and
10mg/kg, IP, respectively) and surgically prepared according to
AAALAC-recommended aseptic techniques. Telemetric devices
(model TRM54P, Telemetry Research, Millar Instruments,
United States of America) were implanted according to the
procedure described by Burmeister et al. (2011). The animals
were divided in three groups: (I) 2K1C treated with HEX in
drinking water (10mg/kg/day) from day 42 to day 49 after renal
artery clipping; (II) 2K1C treated with saline and (III) Sham
group. The dose of HEX (10mg/kg/day) has been chosen based
on our acute studies, where it produced submaximal effects on
blood pressure and heart rate. Blood pressure was recorded
continuously for 1 h from 8:00 a.m. to 9:00 a.m., 1 day per week
for 7 weeks. Heart rate data were derived from the blood pressure
signal oﬄine.
Statistical Analysis
Data are expressed as the mean ± SEM. Statistical analysis
was performed by Student’s t-test or ANOVA Two-Way when
appropriate, using the Graph Pad Prism 5.0 program. Differences
were considered significant when p < 0.05.
Results
HEX Increases Cytosolic NO Levels in Cranial
Mesenteric Arteries Independent on eNOS
Enzyme
Original images from epifluorescence microscopy (Figure 2A)
show cranial mesenteric artery sections incubated with DAF-2
DA and the treatments performed. The data plotted on graph
(Figure 2B) show at first the baseline fluorescence emitted by the
probe without any further treatment (control). After incubation
with HEX the fluorescence significantly increased in samples
when compared to control (33.23 ± 2.29 vs. 10.66 ± 0.62
a.u., respectively, p < 0.05). The nitroglycerin (GTN), the
positive control, also increased the fluorescence (36.92 ± 2.25
vs. 10.66 ± 0.62 a.u., respectively, p < 0.05). Furthermore,
L-NNA did not prevent the increase in fluorescence promoted
by both HEX (32.77 ± 1.65 vs. 33.23 ± 2.29 a.u., respectively,
p > 0.05) and GTN (33.95 ± 1.96 vs. 36.92 ± 2.25 a.u.,
respectively, p > 0.05).
HEX Induces Vasorelaxant Effect in Cranial
Mesenteric Artery of Normotensive Rats, Which
is Independent on Functional Endothelium
As shown in Figure 3A, in phenylephrine pre-contracted
cranial mesenteric artery rings isolated from normotensive rats,
HEX administration (10−10–10−3 M) produces vasorelaxation
in the presence of functional endothelium (ME = 67.0 ±
2.8%; pD2 = 5.84 ± 0.22, n = 7). Moreover, after the
mechanical removal of the endothelium, the vasorelaxation
was potentiated (ME = 100.4 ± 4.1%; pD2 = 5.11 ± 0.12,
n = 10, p < 0.05).
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FIGURE 2 | (A) Representative images of fluorescence in cranial
mesenteric artery sections incubated with DAF-2 DA (10µmol/L), a
fluorescent cell permeable probe for NO. (B) Bars graph showing the
NO production after incubation with only DAF-2 DA (Baseline) and
treatments groups: HEX; nitroglycerin (GTN); HEX + L-NNA; GTN +
L-NNA. Fluorescence was quantified by optic densitometry (arbitrary
units, a.u.). Results are mean ± s.e.m., n = 5 each group. *p < 0.05
vs. Baseline.
FIGURE 3 | Relaxation induced by cumulative addition of HEX
(10−10–10−3 M) in cranial mesenteric artery rings
pre-contracted with PHE (10µM). Results are mean ± s.e.m.
(A) Intact Endothelium vs. Denuded Endothelium, *p < 0.05 vs.
intact endothelium. (B) Denuded Endothelium vs. Denuded
Endothelium + PTIO, *p < 0.05 vs. Denuded Endothelium.
(C) Denuded Endothelium vs. Denuded Endothelium + ODQ,
*p < 0.05 vs. Denuded Endothelium.
Vasorelaxation Induced by HEX is Mediated by
Nitric Oxide Release
In endothelium denuded mesenteric artery rings pre-contracted
with PHE and in the presence of the NO scavenger PTIO,
the vasorelaxant effect of HEX was reduced when compared to
the control (ME = 44.9 ± 9.4 vs. 100.4 ± 4.1%, respectively,
n = 5, p < 0.05). Moreover, the sCG inhibitor ODQ
caused a great decrease in the vasorelaxant effect induced
by HEX, in which the maximum effect was almost abolished
when compared to the control (ME = 38.56 ± 9.7% vs. 100.4
± 4.1%, respectively, n = 5, p < 0.05), as illustrated
in Figures 3B,C.
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Vasorelaxation Induced by HEX is Mediated by
K+ATP Channels
In cranial mesenteric artery rings without functional
endothelium, pretreatment with TEA (3mM), which in
that concentration acts as a non-selective K+ channels blocker,
shifted the concentration-response curve to the right decreasing
the HEX potency (Figure 4A), as observed by the pD2 value
when compared with the control (pD2 = 3.65 ± 0.17 vs. 5.11
± 0.12, respectively, n = 5, p < 0.05). In order to assess the
subtypes of K+ channels, more specific K+ channels blockers
were used. The vasorelaxant responses induced by increasing
concentrations of HEX were not significantly modified by tissue
pre-exposure to TEA (BKCa blocker) or 4-AP (KV blocker). On
the other hand, when GLIB (KATP channel blocker) was used, the
HEX-induced vasodilatation was attenuated (pD2 = 4.38 ± 0.09
vs. 5.11 ± 0.12, n = 6, p < 0.05) without changing in maximum
effect as illustrated in Figures 4B–D.
Acute Administration of HEX Reduces Blood
Pressure and Heart Rate in Hypertensive Rats
Six weeks after 2K1C surgery, the baseline MAP was increased
compared with sham-operated rats (145 ± 3 vs. 120 ± 2mmHg,
respectively, n = 6, p < 0.05). A representative tracing from a
sham operated rat is shown in Figure 5. In normotensive rats,
HEX (1; 5; 10; and 20mg/kg) reduced blood pressure (−20 ±
6; −32 ± 5; −57 ± 9; −76 ± 9mmHg) followed by a slight
tachycardia in first two doses (8 ± 2 and 14 ± 6 bpm) and
significant bradycardia in last two doses (−68 ± 20 and −206 ±
34 bpm) as shown in Figures 6A,B. Furthermore, in conscious
hypertensive rats, HEX (1; 5; 10; and 20mg/kg) reduced blood
pressure in a dose-dependent fashion (−9 ± 5; −12 ± 3; −15 ±
6; −79 ± 10mmHg, respectively), also followed by bradycardia
(−15± 3;−8± 26;−15± 18 and−355± 29 bpm) as shown in
Figures 6C,D.
Sub-chronic Administration of HEX (v.o.)
Produces Anti-Hypertensive Effect in
Renovascular Hypertensive Rats
BP and HR were also evaluated for 7 weeks using telemetry. As
illustrated in Figure 7A, in both 2K1C groups theMAP increased
by 3rd week post clipping (118± 4 and 117± 4mmHg vs. 110±
5mmHg, n = 6 for each group), remaining in ascendancy until
the 6th week (157 ± 5 and 154 ± 5mmHg vs. 106 ± 6mmHg,
n = 6 for each group). In the 7th week the 2K1C group treated
with vehicle remained hypertensive (170 ± 4mmHg) while the
HEX-treated 2K1C rats showed a significant reduction in MAP
(134 ± 6mmHg vs. 170 ± 4mmHg, p < 0.05) as illustrated in
Figure 7B. Sham animals showed no alterations in MAP during
the 7 weeks of treatment. In addition, there was no change in
heart rate among groups over the 7 weeks of the study (data not
show).
Discussion
The major findings of this study are as follows: (i) HEX is
a potential organic nitrate able to release NO and promote
FIGURE 4 | Relaxation induced by cumulative addition of HEX
(10−10–10−3 M) in cranial mesenteric artery rings pre-contracted
with PHE (10µM). (A) Denuded Endothelium vs. Denuded
Endothelium + TEA (3mM). (B) Denuded Endothelium vs. Denuded
Endothelium + TEA (1mM). (C) Denuded Endothelium vs. Denuded
Endothelium + 4-AP. (D) Denuded Endothelium vs. Denuded
Endothelium + GLIB. Results are mean ± s.e.m. *p < 0.05 vs.
Denuded Endothelium.
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relaxation through the activation of the sGC/GMPc/PKG
pathway and KATP channels; (ii) HEX promotes hypotension in
normotensive and hypertensive animals; (iii) oral administration
of HEX for 7 days induces antihypertensive effect in renovascular
hypertensive animals.
FIGURE 5 | Representative tracings from a sham operated rat
illustrating changes in pulse arterial pressure (PAP, mmHg), mean
arterial pressure (MAP, mmHg), and heart rate (HR, bpm) in response
to administration of HEX (1; 5; 10; and 20mg/kg).
The organic nitrates are the most commonly used NO donor
drugs and have been used in the treatment of cardiovascular
diseases for many years. They are often used in association
with beta-blockers drugs and calcium-channel antagonists in
the therapy protocol of ischemic and hypertensive patients. The
major limitation of organic nitrates used in clinical practice is the
rapid development of tolerance following chronic administration
(Miller and Megson, 2007). Thus, despite the existence of
medicines in the same therapeutic class, it is still necessary to
search for new NO donors with clinical utility but fewer side
effects.
Nitric oxide donors induce vascular relaxation by NO
generation like others nitrates (França-Silva et al., 2012a;
FIGURE 7 | Effect of sub-chronic administration of HEX (10mg/kg/day)
in Sham, 2K1C + Saline and 2K1C + HEX groups. (A) Time course of the
variation in MAP. (B) Bar graph showing the MAP in the end of treatments (day
49). Data reported as mean ± s.e.m. *p < 0.05 vs. Sham, #p < 0.05 vs.
2K1C + Saline.
FIGURE 6 | Hypotensive effect induced by intravenous injections of HEX (1; 5; 10; and 20mg/kg). Changes in mean arterial pressure (1MAP) in (A) Sham
and (C) 2K1C rats. Changes in heart rate (1HR) in (B) sham and (D) 2K1C rats. Data presented as mean ± s.e.m. *p < 0.05 vs. saline, #p < 0.05 vs. 10mg/Kg.
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Araújo et al., 2013). In this study (Figure 3) we showed that
HEX induces endothelium-independent vasodilation in cranial
mesenteric artery rings isolated from normotensive rats. In
fact, the vasorelaxation had the maximum effect potentiated
in rings without endothelium. It means that the vascular
endothelium negatively modulates vasorelaxation induced by the
nitrate. Bonaventura et al. (2009) showed a similar result, where
the concentration-response curve to [Ru(terpy)(bdq)NO](3+)-
TERPY, a different NO donor, was less potent in aortic rings
with endothelium preserved due to the uncoupling of eNOS,
resulting in oxidation of BH4, an important cofactor in the
NO production process by eNOS. It is important to highlight
that HEX does not cause uncoupling of eNOS, based on our
preliminary data showing that HEX does not increase superoxide
levels in mesenteric artery (data not shown). Alternatively,
secondary products from the metabolism of HEX could induce
signalingmechanisms on the endothelial cells attenuating normal
vasorelaxation induced by the compound. Of note, both NO
scavenger carboxy-PTIO and the sGC inhibitor ODQ diminished
the HEX effect confirming the involvement of both NO and sGC
in the vasorelaxant effect induced by HEX.
In order to confirm the hypothesis that HEX releases NO, we
used the specific probe DAF-2 DA on vascular smooth muscle
cells (VSMCs) of cranial mesenteric artery from normotensive
rats. Under these experimental conditions, HEX induced an
increase in intracellular NO inmyocytes analyzed by fluorescence
microscopy (Figure 2) indicating that the organic nitrate is
metabolized in biological systems releasing NO. Although this
technique is extremely accurate as the location of the NO
molecule per se, the metabolic pathway and the site of generation
cannot be predicted. Considering the vascular endothelium as
the main physiological source of NO and the absence of studies
about the effects of HEX in endothelial cells, especially its actions
on the eNOS, we used the eNOS selective inhibitor (L-NNA)
to investigate the possible participation of this enzyme in the
HEX-mediated increases in NO. Our data show that even after
blockade of eNOS with L-NNA, HEX was able to increase the
NO levels, indicating that the enzyme is not participating in
the effects induced by HEX. Therefore, there is no activation of
eNOS with subsequent formation of NO. The results obtained
by epifluorescence microscopy confirm the hypothesis that HEX
is an organic nitrate able to donate nitric oxide in VSMCs
without the involvement of eNOS. It is important to highlight
that epifluorescence microscopy for measuring nitric oxide levels
has some limitations. In the presence of NO, divalent cations like
Ca2+ increase DAF-2 fluorescence. The Ca2+ sensitivity of DAF-
2, thus, makes it difficult to distinguish an intracellular Ca2+
increase from an increase in intracellular NO. Measurement of
extracellular NO released from cells by DAF-2 should be less
prone to this problem and thus might be an alternative to the
intracellular bio-imaging by DAF-2 DA. However, this limitation
has been questioned by Leikert et al. (2001).
It is well described that nitric oxide binds to guanylyl cyclase,
increasing cGMP levels and activating PKG. One of the major
target for PKG is the family of potassium channels expressed in
VSMCs. Four types of these channels are found in the VSMCs:
voltage-activated –Kv–; BKCa; inward rectifiers –Kir– (that
include the ATP-sensitive–KATP–) and two-pore domain K+
(K2P) channels (Nelson and Quayle, 1995; Cox and Rusch, 2002;
Jackson, 2005). Activated K+ channels in VSMCs membrane
increase K+ eﬄux causing membrane hyperpolarization and
consequently decreased in Ca2+ entry through voltage-operated
Ca2+ channels making these channels the main contributor
to resting membrane potential and therefore an important
determinant of vascular tone (Billaud et al., 2014).
In order to evaluate the activation of potassium channels
induced by HEX, we used TEA (3mM) for unselectively blockade
of those K+ channels described. Under these experimental
conditions, a decrease in nitrate potency was observed, clearly
demonstrating that some of those channels might be involved
in the vasorelaxant effect induced by HEX, probably via direct
activation by NO and indirect activation by the NO/cGMP/PKG
pathway. Nevertheless, this experimental protocol cannot specify
which channel subtypes were participating in the vasorelaxant
effect induced by HEX. Therefore, specific blockers were used for
the each subtype of channels expressed in VSMCs. TEA (1mM)
acting as a BKCa blocker and 4-AP (1mM) as Kv blocker did
not affect the effects induced by HEX. On the other hand, GLIB
(1mM) shifted the concentration-response curve to the right,
indicating the participation of ATP-sensitive K+ channel on the
vasorelaxation induced by HEX.
In order to evaluate the physiological significance of HEX, the
compound was administered in normotensive and hypertensive
rats. As expected, HEX induced reduction in blood pressure
in all animals in a dose dependent fashion. The renovascular
hypertension model used in this study (2K1C) is recognized
as it involves an increase in renin-angiotensin system activity
and consequently activation of AT1 receptors (Cˇervenka et al.,
2008). Moreover, the 2K1C model is characterized by endothelial
dysfunction, vascular remodeling, increased sympathetic activity,
all of those via AT1R and ROS generation in the CNS and
periphery (Intengan and Schiffrin, 2001; Oliveira-Sales et al.,
2008; Costa et al., 2009). Emerging evidence suggests that the
oxidative stress and endothelial dysfunction have a causal role
in the molecular processes leading to hypertension. Reactive
oxygen species (ROS) may directly alter vascular function or
cause changes in vascular tone by several mechanisms including
altered NO bioavailability or signaling (Schulz et al., 2011). Thus,
the less potent effect of HEX in hypertensive animals may be due
to large concentration of ROS and its interaction with NO.
HEX administration (i.v.) produced bradycardia, unlike other
NO donors such as sodium nitroprusside and nitroglycerin
(Needleman, 1976; Caputi et al., 1980), which induced
tachycardia as a reflex response to the fall in blood pressure.
There are evidence showing that NO donors can enhance
cardiac vagal neurotransmission by sGC activation, increased
acetylcholine release and consequent decrease heart rate (Paton
et al., 2002). In addition, other organic nitrate studied in our
laboratory also produces bradycardia by direct vagal stimulation
dependent of an action in the CNS (França-Silva et al., 2012b).
The presence of bradycardia may represent an important side
effect caused by HEX when compared to other nitric oxide
donors and must be further investigated. In addition, we are
currently running toxicity tests in order to establish the safety
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of the HEX. Furthermore, other pharmacological studies to
establish the half-life of the compound and the characterization
of its potential secondary metabolites are under investigation.
Of note, our preliminary data suggest that HEX does not cause
tolerance as caused by other nitric oxide donors, which seems to
be a promising advantage of this new compound. Regarding its
potency compared to other nitric oxide donors, our present and
previous studies show that HEX is able to increase nitric oxide
with the same magnitude as nitroglycerin (Figure 2) and the
2-nitrate-1,3-dibuthoxypropan (NDBP), a new organic nitrate
developed in our laboratory (França-Silva et al., 2012a,b).
Telemetry was used to evaluate blood pressure and heart rate
during 7 weeks as well as the HEX effects when administered
orally for 7 days when animals were already hypertensive. The
treatment was done by adding HEX in drinking water, so that
each animal received approximately 10mg/kg/day, according to
the daily water intake. Our work showed that BP increased
gradually and significantly over a 5 week period after the clip
implantation, reaching a hypertensive level about 6th week in
agreement with previous studies (Martinez-Maldonado, 1991;
Oliveira-Sales et al., 2014), while the BP in the sham group
was not changed over time. Starting at day 42 post renal
artery clipping, one hypertensive group was treated with HEX
for 7 days and the BP decreased significantly. This result
encourages further studies including clinical trials to investigate
the potential antihypertensive effect of HEX. However, a
better characterization of the side effects, stability, half-life,
and toxicity of the compound must be established before we
move further.
In conclusion, our data show that HEX is a NO donor,
which induces vasorelaxation via NO/cGMP/PKG pathway
and activation of the ATP-sensitive K+ channel and presents
antihypertensive effect in rats with renovascular hypertension.
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